Afficher la notice abrégée

dc.contributor.authorSánchez Tocino, M. Luz 
dc.contributor.authorMiranda-Serrano, Blanca
dc.contributor.authorGracia-Iguacel, Carolina
dc.contributor.authorAlba Peñaranda, Ana María de
dc.contributor.authorMas-Fontao, Sebastian
dc.contributor.authorLópez-González, Antonio
dc.contributor.authorVilloria González, Silvia
dc.contributor.authorPereira-García, Mónica
dc.contributor.authorOrtíz, Alberto
dc.contributor.authorGonzález-Parra, Emilio
dc.date.accessioned2024-01-17T09:28:49Z
dc.date.available2024-01-17T09:28:49Z
dc.date.issued2022-01-13
dc.identifier.urihttp://hdl.handle.net/10366/154328
dc.description.abstractIn 2019, EWGSOP2 proposed 4 steps to diagnose and assess sarcopenia. We aimed to quantify the prevalence of sarcopenia according to the EWGSOP2 diagnostic algorithm and to assess its applicability in elderly patients on hemodialysis. Prospective study of 60 outpatients on chronic hemodialysis aged 75- to 95-years, sarcopenia was assessed according to the 4-step EWGSOP2: Find: Strength, Assistance walking, Rise from a chair, Climb stairs, and Falls (SARC-F); Assess: grip strength by dynamometry (GSD) and sit to stand to sit 5 (STS5); Confirm: appendicular skeletal muscle mass (ASM) by bioimpedance; Severity: gait speed (GS), Timed-Up and Go (TUG), and Short Physical Performance Battery (SPPB). The sequential four steps resulted in a prevalence of confirmed or severe sarcopenia of 20%. Most (97%) patients fulfilled at least one criterion for probable sarcopenia. The sensitivity of SARC-F for confirmed sarcopenia was low (46%). Skipping the SARC-F step increased the prevalence of confirmed and severe sarcopenia to 40% and 37%, respectively. However, 78% of all patients had evidence of dynapenia consistent with severe sarcopenia. Muscle mass (ASM) was normal in 60% of patients, while only 25% had normal muscle strength values (GSD). According to the 4-step EWGSOP2, the prevalence of confirmed or severe sarcopenia was low in elderly hemodialysis patients. The diagnosis of confirmed sarcopenia underestimated the prevalence of dynapenia consistent with severe sarcopenia. Future studies should address whether a 2-step EWGSOP2 assessment (Assess-Severity) is simpler to apply and may provide better prognostic information than 4-step EWGSOP2 in elderly persons on hemodialysis.es_ES
dc.language.isoenges_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectSarcopeniaes_ES
dc.subjectHemodiálisises_ES
dc.subject.meshProspective Studies *
dc.subject.meshSarcopenia *
dc.subject.meshAlgorithms *
dc.titleSarcopenia assessed by 4-step EWGSOP2 in elderly hemodialysis patients: Feasibility and limitationses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1371/JOURNAL.PONE.0261459es_ES
dc.identifier.doi10.1371/journal.pone.0261459
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid35025892
dc.identifier.essn1932-6203
dc.journal.titlePLoS Onees_ES
dc.volume.number17es_ES
dc.issue.number1es_ES
dc.page.initiale0261459es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsalgoritmos *
dc.subject.decsestudios prospectivos *
dc.subject.decssarcopenia *


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Attribution-NonCommercial-NoDerivatives 4.0 Internacional